Randomized Phase III Trial of Cisplatin and Irinotecan versus Cisplatin and Etoposide in Patients with Extensive Stage Small Cell Lung Cancer

Value of Anti-Cancer Drugs in SWOG Phase III Clinical Trials: Evidence from Multiple Evaluation Mechanisms

V Nghiem;R Vaidya;M Banegas;D Hershman;J Unger AcademyHealth Annual Research Meeting (June 23-26, 2018, Seattle, WA), poster #B-335

History of diabetes and outcome among participants 65 or older in SWOG clinical trials

DL Hershman;C Till;JD Wright;S Ramsey;W Barlow;J Unger JCO Clinical Cancer Informatics Nov;1:1-12; DOI: https://doi.org/10.1200/CCI.17.00040 Publishedonlineonascopubs.org/journal/ccion November 20, 2017.

PMid: PMID30657402 | PMC number: PMC6640843

Impact of platinum-sensitivity status on post-progression survival (PPS) of patients with extensive stage small cell lung cancer (ES-SCLC): results from SWOG 0124, a phase III trial of irinotecan/cisplatin(IP) vs. etoposide/cisplatin(EP)

P Lara;J Miao;J Moon;M Redman;D Gandara;K Kelly World Lung Cancer Conference (Dec 4-7, 2016,Vienna, Austria); oral MA11.06

Multitrial evaluation of progression-free survival as a surrogate end point for overall survival in first-line extensive-stage small-cell lung cancer

NR Foster;LA Renfro;SE Schild;M Redman;XY Wang;S Dahlberg;K Ding;PA Bradbury;SS Ramalingam,;DR Gandara;T Shibata;N Saijo;E Vokes;A Adjei;SJ Mandrekar Journal of Thoracic Oncology Jul;10(7):1099-1106

PMid: PMID26134227 | PMC number: PMC4493926

Comparison of survival outcomes among cancer patients treated in and out of clinical trials

J Unger;W Barlow;DP Martin;S Ramsey;M Leblanc;R Etzioni;D Hershman Journal of the National Cancer Institute 106(3):dju002; 2014 Mar 13 [Epub ahead of print];

PMid: PMID24627276 | PMC number: PMC3982777

The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis

MM Dias;J-P Pignon;CS Karapetis;V Boige;B Glimelius;DM Kweekel;PN Lara;Laurent-Puig;E Martinez-Balibrea;D Paez;CJA Punt;M Redman;G Toffoli;M Wadelius;RA McKinnon;MJ Sorich Pharmacogenomics Journal 214(5):424-431;

PMid: PMID24709690 | PMC number: pending

Modeling the relationship between progression-free survival and overall survival: the phase 2/3 trial

M Redman;B Goldman;M LeBlanc;A Schott;LH Baker Clinical Cancer Research, 19(10):2646-2656;

PMid: PMID23669424 | PMC number: PMC4131693

Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globaliztion: the "common arm" approach

PC Mack;DR Gandara;PN Lara, Jr Expert Review of Anticancer Therapy 12(12):1591-1596

PMid: PMID23253224 | PMC number: Reviews are not within the scope of the Public Access Policy

Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124 [PMID20737417; PMC2994945]

P Lara;K Chansky;T Shibata;H Fukuda;T Tamura;J Crowley;M Redman;R Natale;N Saijo;D Gandara Cancer 116(24):5710-5715

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124 [PMID19349543; PMC2684855]

PN Lara;RB Natale;JJ Crowley;HJ Lenz;M Redman;JE Carleton;J Jett;CJ Langer;JP Kuebler;SR Dakhil;K Chansky;DR Gandara Journal of Clinical Oncology 27(15):2530-2535

Cisplatin (Cis) + irinotecan (CPT11) vs. Cis + etoposide (VP16) in extensive stage small cell lung cancer (E-SCLC): final comparative outcomes analysis of JCOG 9511 and SWOG 0124

PN Lara;K Chansky;T Shibata;H Fukuda;T Tamura;N Saijo;HJ Lenz;RB Natale;JJ Crowley;DR Gandara Journal of Clinical Oncology 27:15s, abst. #8027

Final pooled comparative outcomes analysis of JCOG 9511 and SWOG 0124, phase III trials of cisplatin + irinotecan vs. cisplatin + etoposide in extensive stage small cell lung cancer

PN Lara;K Chansky;T Shibata;H Fukuda;T Tamura;J Saijo;HJ Lenz;R Natale;J Crowley;M Redman;DR Gandara Journal of Thoracic Oncology 4(9):suppl 1, abst. D5.7, S396, 2009 (IASLC 13th World Conf on Lung Cancer, oral pres);

Cooperative group research endeavors in small-cell lung cancer: current and future directions [PMID19808190]

R Sangha;P Lara;AA Adjei;P Baas;H Choy;L Gaspar;G Goss;N Saijo;JH Schiller;EE Vokes;D Gandara Clinical Lung Cancer 10(5):322-330

PMC number: n/a (review)

S0124: A randomized phase III trial of cisplatin + irinotecan (PI) versus cisplatin + etoposide (PE) in 671 patients (pts) with extensive stage small cell lung cancer (E-SCLC)

RB Natale;PN Lara;K Chansky;J. Crowley;JR Jett;JE Carleton;JP Kuebler;H Lenz;P Mack;DR Gandara Journal of Clinical Oncology 26(15S):400s, #7512

Progress in small cell lung cancer: the lowest common denominator [PMID18779609]

DR Gandara;PN Lara, Jr.;RB Natale;C Belani Journal of Clinical Oncology 26(26):4236-4238

Cisplatin (Cis)/etoposide (VP16) compared to cis/irinotecan (CPT11) in extensive-stage small cell lung cancer (E-SCLC): pharmacogenomic (PG) and comparative toxicity analysis of JCOG 9511 and SWOG 0124

P Lara Jr;M Redman;H Lenz;M Gordon;T Shibata;H Fukuda;T Tamura;N Saijo;R Natale;DR Gandara Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#7524